Inc. magazine collates an annual list of the fastest-growing private companies in America. This year, 15 of the top 5,000 were related to healthcare, medical devices and biopharma. Many of them were clinical research organizations (CROs) or consultancies that help biopharma companies move through the development, regulatory and commercial processes.
Bioanalytical outsourcing has changed dramatically in the past 30 years. In order to keep up with external market pressures and the complexity of emerging large molecule drugs, pharmaceutical and biotechnology companies have had to reevaluate when it is appropriate to outsource projects, and to what kind of partner.
Finding the right talent is challenging for any organization in any industry, but when you operate in a technical field that requires highly skilled workers, it can be even more difficult. Talent – smart, sophisticated businesspeople who are technologically literate, globally astute, and operationally agile – are the most important corporate resource.
Bioasis Technologies and testing services provider BioAgilytix will partner on the development and validation of bioanalytical methods to support and advance the xB3 -001 program, Bioasis’ lead candidate to treat HER2+ brain cancer.
BioAgilytix and Sword Bio have announced a partnership to improve the offering of bioanalytical services from BioAgilytix, to include an immunoassay detection platform from Sword Bio. The collaboration is expected to meet the growing demand for the enhancement of the performance of immunoassays used for biomarkers, immunogenicity, and pharmacokinetics.
There is no doubt that the biologics market will continue to grow and evolve, and with that growth comes many new opportunities for pharma and biotech companies and the patients they serve. During this period it is vital for our industry to continue to make quality a core focus in every aspect of the large molecule drug development process.
The contract bioanalytical testing services company, BioAgilytix is expanding its technology suite with the addition of Sword Bio's detection platform for immunoassays.The companies this week announced a new collaboration in response to a growing customer need for more robust immunoassays used for biomarkers, immunogenicity, and pharmacokinetics (PK).
The first ‘Trends in Cell-Based Assays’ forum was held this week in Cambridge, hosted by ATCC and BioAgilytix, who partnered with Shire Pharmaceuticals, Takeda Pharmaceuticals, Visterra and the former senior advisor of Science Innovation and Policy for the FDA.
Dr. Arno Kromminga is a certified specialized immunologist with over 20 years of expertise covering the entire cascade of assay strategy and characterization of immune responses against biological therapeutics. In this article he discusses the clinical relevance of immunogenicity.
There is a lot of confusion in the world of biomarker testing when it comes to the terms ‘assay qualification’ and ‘assay validation’. These two terms are not strictly defined and are even used interchangeably at times. This confusion stems from the diverse scientific backgrounds and disciplines of those of us working in the biomarker field.
BioAgilytix, a provider of contract bioanalytical testing services specializing in large molecule bioanalysis, said today it has acquired IPM Biotech for an undisclosed price. BioAgilytix said the deal will combine IPM’s expertise with BioAgilytix’s complementary capabilities in immunogenicity and PK, as well as biomarkers and cell-based assays.
Services
Platforms
